Tirzepatide Shows Noninferior Cardiovascular Safety Compared to Dulaglutide in Type 2 Diabetes

For individuals with Type 2 Diabetes (T2D) and established Atherosclerotic Cardiovascular Disease (ASCVD), managing both glycemic control and cardiovascular risk is paramount. GLP-1 receptor agonists like dulaglutide have demonstrated significant cardiovascular benefits, but the newer dual GLP-1/GIP receptor agonist, tirzepatide, offers superior glycemic control and weight loss. This study addresses the crucial question of whether tirzepatide maintains comparable cardiovascular safety and efficacy to dulaglutide in this high-risk patient population.

The primary finding was that tirzepatide was noninferior to dulaglutide concerning the composite cardiovascular (CV) outcome, defined as cardiovascular death, myocardial infarction (MI), or stroke. This indirect comparison demonstrated that tirzepatide provided comparable cardiovascular safety and efficacy to dulaglutide over a median follow-up of 4 years in adults with T2D and ASCVD. Specifically, indirect treatment effect comparisons showed that tirzepatide versus placebo was associated with significant reductions in CV events, which translated to non-inferiority when compared indirectly to dulaglutide's known effects against placebo. The analysis confirmed that the dual GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) agonism of tirzepatide did not lead to an increased risk of major adverse cardiovascular events compared to the GLP-1 agonism of dulaglutide, indicating similar CV protection.